Observational studyEuropean journal of internal medicine2020
Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study.
Observational study in European journal of internal medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04907890 (Long Term Outcomes in COVID-19 Patients Recruited in the CORIST Project), which is not on this map. Cited by 66 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Long Term Outcomes in COVID-19 Patients Recruited in the CORIST Project: Longitudinal Data and Case-control Study
Who cites it
66 citing papers in PubMed, 3 syntheses or guidelines pooled it, 112 citations in OpenAlex.
- Hydroxychloroquine in the treatment of coronavirus disease 2019: Rapid updated systematic review and meta-analysis.Reviews in medical virology · 2022Pooled it
- A metaresearch study revealed susceptibility of Covid-19 treatment research to white hat bias: first, do no harm.Journal of clinical epidemiology · 2021Pooled it
- Hydroxychloroquine and mortality in COVID-19 patients: a systematic review and a meta-analysis of observational studies and randomized controlled trials.Pathogens and global healthPooled it
- Topical Anti-ulcerogenic Effect of the Beta-adrenergic Blockers on Diabetic Foot Ulcers: Recent Advances and Future Prospectives.Current diabetes reviews · 2024Review
- Efficacy and safety of in-hospital treatment of Covid-19 infection with low-dose hydroxychloroquine and azithromycin in hospitalized patients: A retrospective controlled cohort study.New microbes and new infections · 2023Article
- Different COVID-19 treatments' impact on hospital length of stay.European journal of medical research · 2023Article
- Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine-a possible prevention strategy for COVID-19?Molecular and cellular biochemistry · 2023Review
- COVID-19: Diabetes Perspective-Pathophysiology and Management.Pathogens (Basel, Switzerland) · 2023Review
- Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine.International immunopharmacology · 2022Review
- Immunomodulatory therapy for the management of critically ill patients with COVID-19: A narrative review.World journal of critical care medicine · 2022Article
- Seroprevalence Survey of Anti-SARS-CoV-2 Antibodies in a Population of Emilia-Romagna Region, Northern Italy.International journal of environmental research and public health · 2022Article
- Article
- Off-Label Use of Hydroxychloroquine in COVID-19: Analysis of Reports of Suspected Adverse Reactions From the Italian National Network of Pharmacovigilance.Journal of clinical pharmacology · 2022Article
- Seroprevalence of anti-SARS-CoV-2 antibodies in the Northern Italy population before the COVID-19 second wave.International journal of occupational medicine and environmental health · 2022Article
- Challenges of evidence synthesis during the 2020 COVID pandemic: a scoping review.Journal of clinical epidemiology · 2022Article
- The association of antiviral drugs with COVID-19 morbidity: The retrospective analysis of a nationwide COVID-19 cohort.Frontiers in medicine · 2022Article
- Identification of a dual acting SARS-CoV-2 proteases inhibitor through in silico design and step-by-step biological characterization.European journal of medicinal chemistry · 2021Article
- Comparison between Dexamethasone and Methylprednisolone Therapy in Patients with COVID-19 Pneumonia Admitted to Non-Intensive Medical Units.Journal of clinical medicine · 2021Article
- Comparative effectiveness research in COVID-19 using real-world data: methodological considerations.Journal of comparative effectiveness research · 2021Article
- The association between first and second wave COVID-19 mortality in Italy.BMC public health · 2021Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
1 author at 20 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHydroxychloroquine (HCQ) was proposed as potential treatment for COVID-19.
objectiveWe set-up a multicenter Italian collaboration to investigate the relationship between HCQ therapy and COVID-19 in-hospital mortality.
methodsIn a retrospective observational study, 3,451 unselected patients hospitalized in 33 clinical centers in Italy, from February 19, 2020 to May 23, 2020, with laboratory-confirmed SARS-CoV-2 infection, were analyzed. The primary end-point in a time-to event analysis was in-hospital death, comparing patients who received HCQ with patients who did not. We used multivariable Cox proportional-hazards regression models with inverse probability for treatment weighting by propensity scores, with the addition of subgroup analyses.
resultsOut of 3,451 COVID-19 patients, 76.3% received HCQ. Death rates (per 1,000 person-days) for patients receiving or not HCQ were 8.9 and 15.7, respectively. After adjustment for propensity scores, we found 30% lower risk of death in patients receiving HCQ (HR=0.70; 95%CI: 0.59 to 0.84; E-value=1.67). Secondary analyses yielded similar results. The inverse association of HCQ with inpatient mortality was particularly evident in patients having elevated C-reactive protein at entry.
conclusionsHCQ use was associated with a 30% lower risk of death in COVID-19 hospitalized patients. Within the limits of an observational study and awaiting results from randomized controlled trials, these data do not discourage the use of HCQ in inpatients with COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.